Aug 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
The U.S. has approved RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) as an initial treatment without chemotherapy for patients with advanced lung cancer and EGFR mutations.
Aug 22nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
The U.S. FDA has removed the partial clinical hold previously imposed on MediLink Therapeutics' (Suzhou) Co., Ltd. Phase I trial, which is assessing BNT326/YL202 (NCT05653752) and was disclosed on June 17, 2024.
Apogee Therapeutics Starts Phase 1 Trial for APG990, a New Long-Lasting OX40L Antibody for Atopic Dermatitis and Inflammatory Diseases, with Initial Participants Dosed.